Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements

MET rearrangement-positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2025-04-09
DOI
https://doi.org/10.1158/2159-8290.cd-24-1726
Citations
5
Primary Topic
Liver physiology and pathology
Type
article
Field-Weighted Citation Impact
6.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements

Dimitris Gazgalis, William W. Feng, Jie Jiang, Francesco Facchinetti et al.
5 citations
Cancer Discovery
Liver physiology and pathology
6.61
article

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements

Dimitris Gazgalis, William W. Feng, Jie Jiang, Francesco Facchinetti, Federica Pecci, Edoardo Garbo, Kin-Hung P. Yu, Igor Odintsov, Benjamin Besse, David Planchard, Biagio Ricciuti, Sani H. Kizilbash, Yusuke Sato, Alexis B. Cortot, Danielle Haradon, Emilio Esteban, Jiaxin Niu, Pasi Antero Janne, Pascale Tomasini, Pernelle Lavaud, Mihaela D. Aldea, Jordi Remón, Antoîne Italiano, Koji Haratani, Marcia Cruz‐Correa, Lodovica Zullo, Alessandro Di Federico, Simon Baldacci, Scott Owen, Anna Rachel Minchom, Damien Vasseur, Malini Gandhi, Jianwei Che, Martin Förster, Felix H. Gottlieb, Arushi Saini, Joao V. Alessi, Maisam Makarem, Mark M. Awad, Marie-Anaïs Locquet, Lynette M. Sholl, Seshiru Nakazawa, Pan Chen, Xiaoling Zhang, Kevin Tay, Y. Watanabe, Hoda A. Mahran, Leong Swan Swan, Mythili Sangem
article en
5 citations

Abstract

MET rearrangement-positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.

Cancer DiscoveryVol. 15(6)
University of London (GB), Brigham and Women's Hospital (US), Centre National de la Recherche Scientifique (FR), Royal Marsden NHS Foundation Trust (GB), Mayo Clinic (US), University College London Hospitals NHS Foundation Trust (GB), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Sciences Po Bordeaux (FR), Institute of Cancer Research (GB), Université de Bordeaux (FR), Inserm (FR), University of Puerto Rico, Medical Sciences Campus (PR), Gunma University (JP), University of Puerto Rico System (PR), Aix-Marseille Université (FR), Tottori University of Environmental Studies (JP), Université de Lille (FR), Université Paris-Saclay (FR), Institut Pasteur de Lille (FR), Royal London Hospital (GB), American University of Puerto Rico (PR), McGill University Health Centre (CA), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Lille (FR), Centro Oncológico de Galicia (ES), Dana-Farber Cancer Institute (US), Apollomics (United States) (US), Mayo Clinic in Arizona (US), Hospital Universitario Central de Asturias (ES), Institut Bergonié (FR), National Cancer Centre Singapore (SG), Hôpital de la Timone (FR), Bicêtre Hospital (FR), Banner MD Anderson Cancer Center, University College London (GB), Tottori University (JP), International University of Health and Welfare (JP), University of Bologna (IT)
Good health and well-being
Openalex Percentile: Top 3%
Liver physiology and pathology
6.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.